First-Line Treatment of Advanced Hepatocellular Carcinoma (BCLC Stage C) in Child-Turcotte-Pugh A Cirrhosis

Clinical Scenario

This protocol addresses patients with advanced hepatocellular carcinoma — BCLC Stage C, or BCLC Stage B that is not amenable to or is progressing after locoregional therapy — who have Child-Turcotte-Pugh A cirrhosis, ECOG performance status 0–1, no autoimmune disorder, and no prior liver transplantation.

Key Patient Criteria

Preserved liver function (Child-Turcotte-Pugh A cirrhosis) and maintained performance status (ECOG PS 0–1) are the central eligibility criteria for first-line systemic therapy in this setting. Systemic therapy is recommended for patients meeting these parameters who have advanced or locoregionally refractory disease.

Treatment Approach (partial)

First-line systemic therapy for this population centres on immunotherapy-based combination regimens — atezolizumab plus bevacizumab is one preferred option, with mandatory pre-treatment endoscopic assessment for GI bleeding risk required before initiation.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/HEP.0000000000000466

Systemic therapy should be offered to patients with preserved liver function (Child-Turcotte-Pugh A or well-selected Child-Turcotte-Pugh B cirrhosis), ECOG PS 0-1, who have BCLC Stage C HCC, or BCLC Stage B HCC not amenable to or progressing after locoregional therapy (Level 1, Strong Recommendation).
Patients with advanced HCC who have Child-Turcotte-Pugh A cirrhosis should be offered atezolizumab plus bevacizumab or durvalumab plus tremelimumab as preferred first-line therapy options (Level 2, Strong Recommendation).
Patients considered for atezolizumab plus bevacizumab should undergo an EGD to assess for high-risk stigmata of variceal or other GI bleeding (Level 5, Strong Recommendation).

View source ↗